Skip to main content

Precision Oncology & Biomarker-Driven Deal Benchmarks

Median Upfront
$292M
Range: $163M - $455M
Total Deal Value
$1.9B
Range: $1.2B - $2.5B
Royalty Rate
12.2% - 20%
Tiered up to 24%
Dev Milestones
$391M
Range: $261M - $513M
Model Your Deal

Market Analysis

Precision oncology deals with validated biomarker selection consistently command premium valuations over unselected approaches. Phase 2 biomarker-driven oncology deals achieve a median total deal value of $1.9B, with upfront payments from $163M to $455M. Companion diagnostic strategies, higher response rates, and accelerated regulatory pathways justify the premium.

Milestone structures reflect the higher probability of success for biomarker-selected populations. Development milestones average $391M, while regulatory milestones of $626M reward the faster path to approval via enrichment trial designs. Commercial milestones reach $548M.

Royalty rates for precision oncology deals range from 12.2% to 20% base, escalating to 24%. The higher per-patient efficacy and premium pricing of biomarker-selected therapies support top-tier royalty rates. CDx development costs and IP considerations add complexity to deal negotiations.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How much premium do biomarker-selected oncology deals command?
Biomarker-selected oncology deals at Phase 2 command a median total deal value of $1.9B. The biomarker selection premium typically ranges from 15-30% over unselected approaches at the same clinical stage, driven by higher response rates, cleaner clinical data, and faster regulatory timelines.
How does companion diagnostic (CDx) strategy affect deal terms?
Assets with a validated CDx strategy command higher upfront payments and more favorable milestone structures. The CDx development cost is typically borne by the licensee, but CDx IP ownership and exclusivity provisions are critical negotiation points that can significantly affect royalty rates and overall deal economics.
What biomarkers drive the highest deal premiums in oncology?
Validated predictive biomarkers with FDA-approved CDx assays (e.g., HER2, PD-L1, EGFR mutations, BRCA1/2) command the highest premiums. Novel biomarkers with strong biological rationale but limited clinical validation can also drive premiums if the enrichment strategy shows clear patient selection benefit in early-stage data.

Related Benchmarks

Oncology Deal Overview 2026

View

Small Molecule Deals

View

ADC Deal Benchmarks

View

Phase 2 Deal Benchmarks

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating